Cargando…
Quantification of Bevacizumab Activity Following Treatment of Patients With Ovarian Cancer or Glioblastoma
Highly sensitive reporter-gene assays have been developed that allow both the direct vascular endothelial growth factor (VEGF) neutralizing activity of bevacizumab and the ability of bevacizumab to activate antibody dependent cellular cytotoxicity (ADCC) to be quantified rapidly and in a highly spec...
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7593583/ https://www.ncbi.nlm.nih.gov/pubmed/33178180 http://dx.doi.org/10.3389/fimmu.2020.515556 |